Oncosil Medical Ltd · ASX:OSL
Oncosil Medical — Investor Presentation (August 2022)
18 slides from Oncosil Medical's investor presentation, Aug 3, 2022
Slide 1: Business Update & Key Strategic Priorities for FY 2023
Business Update & Key Strategic Priorities for FY 2023 Nigel Lange - CEO 3 August 2022
Slide 2: OncoSil Medical's targeted approach to pancreatic cancer treatment
OncoSil Medical’s targeted approach is delivering a positive impact in the treatment of pancreatic cancer, aimed at extending the length and quality of life for patients. 2 • FY 2023 Strategic Priorities • 3 August 2022
Slide 3: OncoSil Device Overview
OncoSil™ Device Overview OncoSil™ is intended OncoSil™ is a single-use OncoSil™ is implanted 98% of all radiation is for the treatment of brachytherapy device directly into a pancreatic delivered within 81 days locally advanced comprised of microparticles tumour via injection under of injection caus
Slide 4: A Year of Significant Achievement in Readying the Device for Commercialisation
A Year of Significant Achievement in Readying the Device for Commercialisation Bupa UK Approves Reimbursement for First Commercial Pancreas Cancer Treatment OncoSilTM in the UK at The London Clinic With The OncoSilTM Device In Spain PanCO Clinical Study on Second patient treated in Spain proceeds €3
Slide 5: Key Inflection Points
Key Inflection Points 1. Strongly increasing annual revenues. Work collaboratively with FDA to facilitate approval for HDE in dCCA (distal 2. cholangiocarcinoma). 3. Operational improvements. 4. Strategic initiatives and partnerships. 5. Pancreatic cancer will be Australia’s 2nd biggest cancer kille
Slide 6: FY 2023 Deliverables
FY 2023 Deliverables 1. Accelerate commercial sales of the OncoSilTM device. 2. Pursue additional reimbursement programs. 3. Geographic expansion of sales. 4. Expand authorised user base. 5. Expand clinical data. 6. Progress FDA discussion for HDE in dCCA (distal cholangiocarcinoma). 7. Diversify ma
Slide 7: Accelerate commercial sales of the OncoSil device
1. Accelerate commercial sales of the OncoSilTM device To continue geographic expansion into additional targeted markets where OncoSilTM has approval to sell and in markets in which we are Deliverables Achieve first sales with other countries within the registered where the CE Mark is • EU and the U
Slide 8: Pursue additional reimbursement programs
2. Pursue additional reimbursement programs Greater sales of the OncoSilTM device will occur once the Company secures additional reimbursement for patient treatments either through national reimbursement or private Deliverables health insurance coverage. • Expand private health insurance coverage in
Slide 9: Geographic expansion of sales
3. Geographic expansion of sales OncoSilTM to diversify geographic sales in FY 2023 through direct sales staff and distributors in selected markets. Deliverables • Achieve first sales with other countries within the EU and the UK where the OncoSilTM device is approved Sales discussions have also wit
Slide 10: Expand authorised user base
4. Expand authorised user base Undertaking a percutaneous clinical trial is important in that it potentially expands the authorised user base who can safely administer the OncoSilTM device. Deliverables • To commence percutaneous clinical trial. 10 • FY 2023 Strategic Priorities • 3 August 2022
Slide 11: Expansion of clinical data
5. Expansion of clinical data OncoSil seeks to continue clinical trial activities aimed at enhancing data supporting the usage of the The Company is focused on cost-effective clinical evidence OncoSilTM device and to enable generation. reimbursement. Deliverables • Commence patient recruitment for t
Slide 12: Progress FDA discussion for HDE in dCCA (distal cholangiocarcinoma)
6. Progress FDA discussion for HDE in dCCA (distal cholangiocarcinoma) Deliverables • Provide additional data to the FDA. • Obtain FDA approval for the HDE in dCCA. 12 • FY 2023 Strategic Priorities • 3 August 2022
Slide 13: Diversify manufacturing to reduce production costs and gain economies of scale
7. Diversify manufacturing to reduce production costs and gain economies of scale OncoSil has been in the process of reviewing the current supply chain to ensure that inefficiencies are removed and that costs are reduced Deliverables • Execute agreements with additional nuclear reactors. once scalin
Slide 14: Investigate device usage in other solid tumour indications
8. Investigate device usage in other solid tumour indications, potentially via strategic partnership Deliverables • Identify potential use of the OncoSilTM device in other solid tumours. • Identify suitable industry partners to assist in further development of the device outside of the current appro
Slide 15: Strategic initiatives and partnerships
9. Strategic initiatives and partnerships To enable non-dilutive funding, OncoSil will be exploring potential strategic initiatives and partnerships during FY 2023. Deliverables • Identify markets where potential out-licensing opportunities could be executed. 15 • FY 2023 Strategic Priorities • 3 Au
Slide 16: Management Team with a Depth of Experience and Expertise
Management Team with a Depth of Experience and Expertise Nigel Lange Managing Director & CEO 30+ years experience in medical device industry. Served as Group COO and Interim Group CEO of Sirtex Medical Dr Jon Bell MD David Turner Henk Tissing Chief Medical Officer Head of Medical Affairs Director of
Slide 17: Disclaimer
Disclaimer This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (OncoSil or the Company) additional analysis of existing data, and new data; unexpected regulatory actions or delays, or to provide a general overview of the Company. This Presentation and the information contained gover
Slide 18: Nigel Lange
Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com OncoSil Medical Ltd www.oncosil.com T: +49 30 40817 4058
OncoSil Medical — Investor Presentation (August 2022) on 6ix